All lobbying filings

THE NICKLES GROUP, LLC

Lobbying for MERCK & CO. INC. · Manufacturer of pharmaceuticals

Filing 4th Quarter - Report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 9

Centers For Disease Control & Prevention (CDC)
Centers For Medicare and Medicaid Services (CMS)
Executive Office of the President (EOP)
Food & Drug Administration (FDA)
Health & Human Services, Dept of (HHS)
HOUSE OF REPRESENTATIVES
Office of Management & Budget (OMB)
SENATE
White House Office

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 4

HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act
HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 4

Health Issues

Issues related to pharmacy benefit management reforms. Issues related to vaccine policy. Issues related to supply chain and domestic manufacturing capacity.

Medicare/Medicaid

Issues related to drug pricing and implementation of the Inflation Reduction Act. H.R. 946/S. 1862, ORPHAN Cures Act. H.R. 1492, the Ensuring Pathways to Innovative Cures Act. Issues related to pharmacy benefit management reforms. Issues related to Most Favored Nation drug pricing.

Taxation/Internal Revenue Code

Monitored implementation of H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act, as it relates to corporate taxes.

Trade (domestic/foreign)

Issues related to tariffs.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.